Tag: Imipramine

While Selective Serotonin Reuptake Inhibitors (SSRIs) are the first-line pharmacologic treatment for anxiety, tricyclic antidepressants (TCAs) remain a viable option for patients who do not respond to or cannot tolerate newer drugs. Determining which TCA is best for anxiety is a complex decision that depends on the specific anxiety disorder, individual side effect tolerance, and other co-occurring conditions.

Studies show that approximately 27.5% of patients with overactive bladder (OAB) also have depression [1.6.2]. For these individuals, the key question is: **what is the best antidepressant for overactive bladder** that can simultaneously address both conditions?

In 2021, an estimated 21 million adults in the United States had at least one major depressive episode [1.8.1]. For those exploring treatment, a common question is, **which antidepressants are tricyclic?** This older class of medication remains a vital option for various conditions.

First introduced in the late 1950s, tricyclic antidepressants (TCAs) were among the earliest medications used for depression. While newer options are often prescribed first, understanding what medications are considered TCAs is important, as they remain valuable for specific conditions and treatment-resistant cases.

Shamin Tablet is a prescription medication containing the active ingredient imipramine, a type of tricyclic antidepressant (TCA). While TCAs are an older class of drugs, Shamin (referred to as Shimin in some contexts) is primarily used to treat major depressive disorder and manage nocturnal enuresis (bedwetting) in children.

Originally developed in the 1950s, imipramine was the first tricyclic antidepressant (TCA) to be marketed, and today, imipramine has distinct applications in both pediatric and adult medicine. While a low dose like 25 mg can be part of a starting regimen for depression, it is also a standard starting point for treating nocturnal enuresis, or bedwetting, in children.